{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:52:14Z","timestamp":1791571934184,"version":"4.3.4"},"reference-count":34,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>Iron deficiency affects approximately half of patients with heart failure with preserved ejection fraction (HFpEF) and impairs functional capacity, yet evidence for intravenous (IV) iron in this population is limited. We evaluated the effect of IV iron on functional, biochemical, biomarker, and clinical outcomes in HFpEF. This systematic review followed PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) 2020 and was prospectively registered [International Prospective Register of Systematic Reviews (PROSPERO) CRD420261360828]. Four databases were searched on April 11, 2026. Eligible studies enrolled adults with HFpEF and iron deficiency receiving IV iron, with at least 4 weeks of follow-up. Two reviewers independently screened records, extracted data, and assessed risk of bias. Because few studies were eligible and heterogeneity was substantial, findings were synthesized narratively without meta-analysis in accordance with the synthesis without meta-analysis guideline, and certainty was rated using the Grading of Recommendations Assessment, Development and Evaluation framework. Seven reports of 6 studies were included: 1 randomized trial, 2 controlled observational studies, and 3 single-arm before-after studies. Across studies, IV iron consistently increased ferritin, transferrin saturation, and hemoglobin. The randomized trial improved 6-minute walking distance but not functional class or quality of life, and was stopped early. Effects on natriuretic peptide concentrations were inconsistent. The 2 controlled studies disagreed on clinical events: a propensity-matched analysis reported fewer hospitalizations, whereas a registry found no benefit. Certainty of evidence ranged from very low to moderate. In HFpEF, IV iron reliably corrects iron indices, but a clinical benefit remains unproven, and the evidence base is sparse and largely uncontrolled. Adequately powered randomized trials are required.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/crd.0000000000001479","type":"journal-article","created":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:10:36Z","timestamp":1791569436000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Intravenous Iron Supplementation in Heart Failure with Preserved Ejection Fraction"],"prefix":"10.1097","author":[{"given":"Arfaan","family":"Sheriff","sequence":"first","affiliation":[{"name":"School of Population Health, University of New South Wales (UNSW Sydney), Sydney, New South Wales, Australia"},{"name":"Department of Cardiology, Blacktown Hospital, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex R.","family":"Qin","sequence":"additional","affiliation":[{"name":"School of Mathematics and Statistics, The University of Sydney, Sydney, New South Wales, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abyaan","family":"Sheriff","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences and Medicine, Bond University, Gold Coast, Queensland, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"R1-20261009","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1093\/cvr\/cvac013","article-title":"Global burden of heart failure: a comprehensive and updated review of epidemiology.","volume":"118","author":"Savarese","year":"2023","journal-title":"Cardiovasc Res"},{"key":"R2-20261009","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.cardfail.2023.03.025","article-title":"Iron deficiency in heart failure: a scientific statement from the Heart Failure Society of America.","volume":"29","author":"Beavers","year":"2023","journal-title":"J Card Fail"},{"key":"R3-20261009","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ahj.2013.01.017","article-title":"Iron deficiency in chronic heart failure: an international pooled analysis.","volume":"165","author":"Klip","year":"2013","journal-title":"Am Heart J"},{"key":"R4-20261009","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ejhf.1154","article-title":"Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function.","volume":"20","author":"Hoes","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"R5-20261009","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/j.jacc.2011.04.040","article-title":"Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival.","volume":"58","author":"Okonko","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"R6-20261009","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/nrcardio.2011.77","article-title":"Anemia and iron deficiency in heart failure: mechanisms and therapeutic approaches.","volume":"8","author":"van Veldhuisen","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"R7-20261009","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1093\/eurheartj\/ehz680","article-title":"Iron deficiency in worsening heart failure is associated with reduced estimated protein intake, fluid retention, inflammation, and antiplatelet use.","volume":"40","author":"van der Wal","year":"2019","journal-title":"Eur Heart J"},{"key":"R8-20261009","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1056\/NEJMoa0908355","article-title":"Ferric carboxymaltose in patients with heart failure and iron deficiency.","volume":"361","author":"Anker","year":"2009","journal-title":"N Engl J Med"},{"key":"R9-20261009","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/eurheartj\/ehu385","article-title":"Beneficial effects of long-term intravenous iron therapy with ferric carboxymaltose in patients with symptomatic heart failure and iron deficiency.","volume":"36","author":"Ponikowski","year":"2015","journal-title":"Eur Heart J"},{"key":"R10-20261009","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(20)32339-4","article-title":"Ferric carboxymaltose for iron deficiency at discharge after acute heart failure: a multicentre, double-blind, randomised, controlled trial.","volume":"396","author":"Ponikowski","year":"2020","journal-title":"Lancet"},{"key":"R11-20261009","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1016\/S0140-6736(22)02083-9","article-title":"Intravenous ferric derisomaltose in patients with heart failure and iron deficiency in the UK (IRONMAN): an investigator-initiated, prospective, randomised, open-label, blinded-endpoint trial.","volume":"400","author":"Kalra","year":"2022","journal-title":"Lancet"},{"key":"R12-20261009","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa2304968","article-title":"Ferric carboxymaltose in heart failure with iron deficiency.","volume":"389","author":"Mentz","year":"2023","journal-title":"N Engl J Med"},{"key":"R13-20261009","doi-asserted-by":"crossref","first-page":"5077","DOI":"10.1093\/eurheartj\/ehad586","article-title":"Efficacy of ferric carboxymaltose in heart failure with iron deficiency: an individual patient data meta-analysis.","volume":"44","author":"Ponikowski","year":"2023","journal-title":"Eur Heart J"},{"key":"R14-20261009","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines.","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R15-20261009","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure.","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"R16-20261009","doi-asserted-by":"crossref","first-page":"e001012","DOI":"10.1136\/openhrt-2019-001012","article-title":"Iron deficiency in heart failure with preserved ejection fraction: a systematic review and meta-analysis.","volume":"6","author":"Beale","year":"2019","journal-title":"Open Heart"},{"key":"R17-20261009","doi-asserted-by":"crossref","first-page":"3789","DOI":"10.1093\/eurheartj\/ehae479","article-title":"Ferric carboxymaltose and exercise capacity in heart failure with preserved ejection fraction and iron deficiency: the FAIR-HFpEF trial.","volume":"45","author":"von Haehling","year":"2024","journal-title":"Eur Heart J"},{"key":"R18-20261009","first-page":"101723","article-title":"Intravenous iron for iron deficiency in heart failure with preserved ejection fraction. A multivariate analysis.","volume":"59","author":"Noverraz","year":"2025","journal-title":"Int J Cardiol Heart Vasc"},{"key":"R19-20261009","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R20-20261009","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range.","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"R21-20261009","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R22-20261009","doi-asserted-by":"crossref","first-page":"i4919","DOI":"10.1136\/bmj.i4919","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions.","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ"},{"key":"R23-20261009","doi-asserted-by":"crossref","first-page":"l6890","DOI":"10.1136\/bmj.l6890","article-title":"Synthesis without meta-analysis (SWiM) in systematic reviews: reporting guideline.","volume":"368","author":"Campbell","year":"2020","journal-title":"BMJ"},{"key":"R24-20261009","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials.","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"R25-20261009","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations.","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"R26-20261009","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfae069.644","article-title":"Evaluation of the effect of IV iron therapy on eGFR and pro-BNP in patients with chronic kidney disease and heart failure with preserved EF [abstract 2770].","volume":"39","author":"Helvaci","year":"2024","journal-title":"Nephrol Dial Transplant"},{"key":"R27-20261009","first-page":"146","article-title":"Ferric carboxymaltose reduces NT-proBNP and enhances functional status in chronic kidney disease and heart failure with preserved ejection fraction.","volume":"45","author":"Helvaci","year":"2026","journal-title":"Rev Nefrol Dial Traspl"},{"key":"R28-20261009","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.rccl.2023.06.002","article-title":"Ferric carboxymaltose for patients with heart failure in all-range ejection fraction.","volume":"58","author":"Esteban-Fern\u00e1ndez","year":"2023","journal-title":"REC CardioClinics"},{"key":"R29-20261009","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/ehf2.13753","article-title":"Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction.","volume":"9","author":"L\u00f3pez-Vilella","year":"2022","journal-title":"ESC Heart Fail"},{"key":"R30-20261009","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cardfail.2025.11.420","article-title":"Long-term cardiovascular outcomes of IV ferric carboxymaltose in patients with heart failure with preserved ejection fraction and iron deficiency: a propensity-matched retrospective analysis","volume":"32","author":"Doshi","year":"2026","journal-title":"J Card Fail"},{"key":"R31-20261009","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1001\/jama.2025.3833","article-title":"Intravenous ferric carboxymaltose in heart failure with iron deficiency: the FAIR-HF2-DZHK05 randomised clinical trial.","volume":"333","author":"Anker","year":"2025","journal-title":"JAMA"},{"key":"R32-20261009","doi-asserted-by":"crossref","first-page":"2640","DOI":"10.1038\/s41591-025-03671-1","article-title":"Systematic review and meta-analysis of intravenous iron therapy for patients with heart failure and iron deficiency.","volume":"31","author":"Anker","year":"2025","journal-title":"Nat Med"},{"key":"R33-20261009","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1161\/CIRCULATIONAHA.114.010637","article-title":"Phenomapping for novel classification of heart failure with preserved ejection fraction.","volume":"131","author":"Shah","year":"2015","journal-title":"Circulation"},{"key":"R34-20261009","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction.","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000001479","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T18:10:40Z","timestamp":1791569440000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/CRD.0000000000001479"}},"subtitle":["A Systematic Review"],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":34,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001479","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]}}}